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PREPARATION AND ENCAPSULATION OF 
DIORGANOTIN(IV) AS POTENTIAL ANTI CANCER DRUGS
Cancer is one of the leading cause of death worldwide. Metal-based drugs such as cisplatin and other platinum compounds
have had a huge impact in the treatment of cancer and are applied in many anticancer chemotherapeutic treatments. The
success of these compounds has led to the discovery of other new metal-based anticancer drugs. However, as there might be
a lack of selectivity when the trial compounds enter the cell, the drugs might potentially kill all dividing cells. In order to
minimize the severe side effects, localised applications of drugs are important. Therefore, the application of a drug delivery
system is crucial. The present work highlights the preparation of several diorganotin Schiff base complexes and its anticancer
activity. Also, we prepared and characterized niosomes containing diorganotin complexes as anticancer drugs by a
microencapsulation vesicle method (MCV) [1]. The encapsulation efficiency (%EE), percentage of drug loading (%DL) as well
as the particle size, zeta potential and drug release of the niosomes [2] will be studied.
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RESULTS AND DISCUSSION
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Compound 1 2 3 4 Paclitaxel 5-Fluorouracil
IC50 (g ml
-1 )
[for HT29]
5.0 6.0 2.3 3.0 - -
%EE >99 97 >99 >99 80 55
%DL 89 86 89 88 31 4
Note: 
The %EE and %DL were 
calculated according to 
[3]. 
Figure 2: In vitro release of 3 formulation in 100 days
Figure 1: Photomicrograph of 
3 niosomes
Table 2: Size and zeta potential      
of 3
Method MCV
Polydispersity index 
(PDI)
0.4 
Size distribution (nm) 724 ± 289 (75%)
207 ± 52 (23%)
5370 ±329 (2%)
Zeta Potential, mV -33 ± 5
Niosomes (sugar surfactant)
Table 1: % EE, % DL of compounds and reference drugs 
Organotin compounds
(as potential drugs)
Aqueous cavity
MCV 
method
